Resource Logo
NLM AIDSLINE

Adjuvants that enhance priming of cytotoxic T cells to a Kb-restricted epitope processed from exogenous but not endogenous hepatitis B surface antigen.




 

Int Immunol. 1999 Jul;11(7):1093-102. Unique Identifier : AIDSLINE

Intramuscular (i.m.) or s.c. injection of plasmid DNA encoding hepatitis B small surface antigen (HBsAg) primes potent MHC I-restricted cytotoxic T lymphocyte (CTL) responses in H-2(d) (BALB/c) and H-2(b) (C57BL/6) mice. In contrast, i.m. or s.c. injection of exogenous HBsAg particles without adjuvants primes CTL responses in 'high responder' H-2(d) but not 'low responder' H-2(b) mice. We have shown that processing of exogenous but not endogenous HBsAg generates the Kb-binding S208-215 peptide ILSPFLPL. This system allowed us to optimize conditions for stimulating murine CTL responses to exogenous antigen by identifying adjuvants that facilitate priming of Kb-restricted CTL by injecting recombinant HBsAg particles into 'low responder' H-2(b) mice. Synthetic oligodeoxynucleotides with immunostimulating sequences or the recombinant cytokine IL-12 efficiently enhanced priming of CTL to exogenous HBsAg. Hence, the adjuvanticity of DNA sequences that induce Th1 cytokines facilitate priming of MHC I-restricted T cell responses to exogenous antigen and are therefore of potential value in formulating vaccines designed to enhance CTL priming to exogenous antigen.

JOURNAL ARTICLE Adjuvants, Immunologic/*PHARMACOLOGY Animal Antigen Presentation Cytokines/BIOSYNTHESIS/IMMUNOLOGY Epitopes, T-Lymphocyte/*IMMUNOLOGY Female H-2 Antigens/*IMMUNOLOGY Hepatitis B Surface Antigens/*ADMINISTRATION & DOSAGE/GENETICS/ *PHYSIOLOGY Injections, Intramuscular Interleukin-12/IMMUNOLOGY/PHARMACOLOGY Male Mice Mice, Inbred BALB C Mice, Inbred C57BL Support, Non-U.S. Gov't T-Lymphocytes, Cytotoxic/*IMMUNOLOGY/METABOLISM Th1 Cells/IMMUNOLOGY/METABOLISM



 




Information in this article was accurate in November 30, 1999. The state of the art may have changed since the publication date. This material is designed to support, not replace, the relationship that exists between you and your doctor. Always discuss treatment options with a doctor who specializes in treating HIV.